Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Beatriz Rodriguez-Sanchez, Isaac Aranda-Reneo, Juan Oliva-Moreno & Julio Lopez-Bastida. (2021) Assessing the Effect of Including Social Costs in Economic Evaluations of Diabetes-Related Interventions: A Systematic Review. ClinicoEconomics and Outcomes Research 13, pages 307-334.
Read now
Read now
Johan Jendle, Åsa Ericsson, Bertil Ekman, Stefan Sjöberg, Jens Gundgaard, João da Rocha Fernandes, Ann-Charlotte Mårdby, Barnaby Hunt, Samuel J. P. Malkin & Maria Thunander. (2020) Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective. Journal of Medical Economics 23:11, pages 1311-1320.
Read now
Read now
Steffen Haldrup, Annunziata Lapolla, Jens Gundgaard & Michael L. Wolden. (2020) Cost-effectiveness of switching to insulin degludec from other basal insulins in real-world clinical practice in Italy. Journal of Medical Economics 23:3, pages 271-279.
Read now
Read now
Wendy S. Lane, James Weatherall, Jens Gundgaard & Richard F. Pollock. (2018) Insulin degludec versus insulin glargine U100 for patients with type 1 or type 2 diabetes in the US: a budget impact analysis with rebate tables. Journal of Medical Economics 21:2, pages 144-151.
Read now
Read now
Pedro Mezquita-Raya, Josep Darbà, Meritxell Ascanio & Antonio Ramírez de Arellano. (2017) Cost-effectiveness analysis of insulin degludec compared with insulin glargine u100 for the management of type 1 and type 2 diabetes mellitus – from the Spanish National Health System perspective. Expert Review of Pharmacoeconomics & Outcomes Research 17:6, pages 587-595.
Read now
Read now
Lena Landstedt-Hallin, Jens Gundgaard, Åsa Ericsson & Susanne Ellfors-Zetterlund. (2017) Cost-effectiveness of switching to insulin degludec from other basal insulins: evidence from Swedish real-world data. Current Medical Research and Opinion 33:4, pages 647-655.
Read now
Read now
R. F. Pollock & C. K. Tikkanen. (2017) A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark. Journal of Medical Economics 20:3, pages 213-220.
Read now
Read now
Elizabeth M Lamos, Lisa M Younk & Stephen N Davis. (2016) Concentrated insulins: the new basal insulins. Therapeutics and Clinical Risk Management 12, pages 389-400.
Read now
Read now
Marc Evans, Phil McEwan & Volker Foos. (2015) Insulin degludec early clinical experience: does the promise from the clinical trials translate into clinical practice—a case-based evaluation. Journal of Medical Economics 18:2, pages 96-105.
Read now
Read now
Victoria Stokes & Stephen CL Gough. (2014) Recent advances with insulin degludec for the treatment of Type 2 diabetes. Expert Review of Endocrinology & Metabolism 9:4, pages 301-312.
Read now
Read now
Articles from other publishers (13)
Yotsapon Thewjitcharoen, Nalin Yenseung, Areeya Malidaeng, Siriwan Butadej, Phawinpon Chotwanvirat, Sirinate Krittiyawong, Chattip Thammawiwat & Thep Himathongkam. (2019) Effectiveness of Insulin Degludec in Thai Patients with Diabetes Mellitus: Real-World Evidence From a Specialized Diabetes Center. Experimental and Clinical Endocrinology & Diabetes 129:09, pages 666-673.
Crossref
Crossref
Alice Cheng, Timothy S. Bailey, Didac Mauricio & Ronan Roussel. (2020)
Insulin glargine 300 U/
mL
and insulin degludec: A review of the current evidence comparing these two second‐generation basal insulin analogues
. Diabetes/Metabolism Research and Reviews 36:7.
Crossref
Crossref
Monika Russel-Szymczyk, Vasil Valov, Alexandra Savova & Manoela Manova. (2019) Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria. BMC Endocrine Disorders 19:1.
Crossref
Crossref
Richard F. Pollock, William J. Valentine, Steven P. Marso, Andreas Andersen, Jens Gundgaard, Nino Hallén, Deniz Tutkunkardas, Elizabeth A. Magnuson & John B. Buse. (2019) Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16). Applied Health Economics and Health Policy 17:5, pages 615-627.
Crossref
Crossref
Richard F. Pollock, Simon Heller, Thomas R. Pieber, Vincent Woo, Jens Gundgaard, Nino Hallén, Maria Luckevich, Deniz Tutkunkardas & Bernard Zinman. (2019) Short‐term cost‐utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9). Diabetes, Obesity and Metabolism 21:7, pages 1706-1714.
Crossref
Crossref
Arnaldo Moura Neto & Maria Tereza Martins Ferrari. (2018) Efficacy, safety and clinical use of newer basal insulins analogs. Endocrinology&Metabolism International Journal 6:3.
Crossref
Crossref
Nebojša Lalić, Monika Russel-Szymczyk, Marina Culic, Christian Klyver Tikkanen & Barrie Chubb. (2018) Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U100 in Patients with Type 1 and Type 2 Diabetes Mellitus in Serbia. Diabetes Therapy 9:3, pages 1201-1216.
Crossref
Crossref
Marc Evans, Barrie Chubb & Jens Gundgaard. (2017) Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus. Diabetes Therapy 8:2, pages 275-291.
Crossref
Crossref
Asrul Akmal Shafie, Chin Hui Ng, Yui Ping Tan & Nathorn Chaiyakunapruk. (2016) Systematic Review of the Cost Effectiveness of Insulin Analogues in Type 1 and Type 2 Diabetes Mellitus. PharmacoEconomics 35:2, pages 141-162.
Crossref
Crossref
Marc Evans, Jens Gundgaard & Brian Bekker Hansen. (2016) Cost-Effectiveness of Insulin Degludec/Insulin Aspart Versus Biphasic Insulin Aspart in Patients with Type 2 Diabetes from a Danish Health-Care Perspective. Diabetes Therapy 7:4, pages 809-823.
Crossref
Crossref
Jiten Vora, Bertrand Cariou, Marc Evans, Jorge Luiz Gross, Stewart Harris, Lena Landstedt-Hallin, Ambrish Mithal, Martín Rodríguez Rodriguez & Luigi Meneghini. (2015) Clinical use of insulin degludec. Diabetes Research and Clinical Practice 109:1, pages 19-31.
Crossref
Crossref
Marc Evans & Phil McEwan. (2015) Clinical and cost–effectiveness of insulin degludec: from clinical trials to clinical practice. Journal of Comparative Effectiveness Research 4:3, pages 279-286.
Crossref
Crossref
Aliasghar A. Kiadaliri, Ulf G. Gerdtham, Bjorn Eliasson & Katarina Steen Carlsson. (2014) Cost–Utility Analysis of Glucagon-Like Peptide-1 Agonists Compared with Dipeptidyl Peptidase-4 Inhibitors or Neutral Protamine Hagedorn Basal Insulin as Add-On to Metformin in Type 2 Diabetes in Sweden. Diabetes Therapy 5:2, pages 591-607.
Crossref
Crossref